A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
- Status
- COMPLETED
- Phase
- PHASE2
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
- Status
- UNKNOWN
- Phase
- PHASE3
Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.
- Status
- UNKNOWN
- Phase
- N/A
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
- Status
- COMPLETED
- Phase
- PHASE1
Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment
- Status
- WITHDRAWN
- Phase
- PHASE3
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Rituximab and RASi in Patients with IgAN
- Status
- COMPLETED
- Phase
- PHASE4
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Rituximab for Idiopathic Nephrotic Syndrome
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
- Status
- WITHDRAWN
- Phase
- PHASE2
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1